

# Ambrogio Orlando

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4932356/ambrogio-orlando-publications-by-citations.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

90  
papers

2,254  
citations

23  
h-index

45  
g-index

95  
ext. papers

2,723  
ext. citations

4.7  
avg, IF

4.79  
L-index

#	Paper	IF	Citations
90	Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 1104-13	59.2	304
89	Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2011</b> , 9, 30-5	6.9	253
88	Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, 514-24	0.7	199
87	The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. <i>Digestive and Liver Disease</i> , <b>2011</b> , 43, 1-20	3.3	101
86	The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. <i>Inflammatory Bowel Diseases</i> , <b>2017</b> , 23, 233-243	4.5	96
85	Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in postoperative Crohn's disease. <i>Gastroenterology</i> , <b>2008</b> , 135, 1500-9	13.3	72
84	Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease. <i>Autoimmunity Reviews</i> , <b>2014</b> , 13, 822-30	13.6	63
83	The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. <i>Autoimmunity Reviews</i> , <b>2014</b> , 13, 751-5	13.6	59
82	Inter-observer agreement in endoscopic scoring systems: preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 969-73	3.3	58
81	Adalimumab in active ulcerative colitis: a "real-life" observational study. <i>Digestive and Liver Disease</i> , <b>2013</b> , 45, 738-43	3.3	57
80	Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 9675-90	5.6	51
79	Early post-operative endoscopic recurrence in Crohn's disease patients: data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort. <i>Journal of Crohn's and Colitis</i> , <b>2014</b> , 8, 1217-21	1.5	38
78	Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 963-8	3.3	36
77	Gastrointestinal lesions associated with spondyloarthropathies. <i>World Journal of Gastroenterology</i> , <b>2009</b> , 15, 2443-8	5.6	36
76	The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, 568-579	4.5	35
75	Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 338-358	3.3	34
74	Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 604-617	3.3	34

73	Clinical implications of mucosal healing in the management of patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , <b>2013</b> , 45, 986-91	3.3	33
72	Cancer in Crohn's Disease patients treated with infliximab: a long-term multicenter matched pair study. <i>Inflammatory Bowel Diseases</i> , <b>2011</b> , 17, 758-66	4.5	33
71	Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, e31	2.4	29
70	Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 360-70	3.3	29
69	COVID-19 in patients with inflammatory bowel disease: A systematic review of clinical data. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 1222-1227	3.3	26
68	Diagnostic and vaccine strategies to prevent infections in patients with inflammatory bowel disease. <i>Journal of Infection</i> , <b>2017</b> , 74, 433-441	18.9	23
67	Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease. <i>Expert Opinion on Biological Therapy</i> , <b>2019</b> , 19, 89-98	5.4	23
66	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 632-639	3.3	22
65	The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases. <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 675-681	3.3	22
64	Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study. <i>Journal of Crohns and Colitis</i> , <b>2016</b> , 10, 913-24	1.5	21
63	Training Programs on Endoscopic Scoring Systems for Inflammatory Bowel Disease Lead to a Significant Increase in Interobserver Agreement Among Community Gastroenterologists. <i>Journal of Crohns and Colitis</i> , <b>2017</b> , 11, 556-561	1.5	21
62	Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study. <i>Inflammatory Bowel Diseases</i> , <b>2020</b> , 26, 450-459	4.5	20
61	Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, 1805-1812	4.5	19
60	A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor- $\alpha$ Inhibitor-naïve and Non-naïve Patients With Crohn's Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , <b>2019</b> , 13, 209-217	1.5	19
59	The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> , 27, 182-189	4.5	19
58	Patient and physician views on the quality of care in inflammatory bowel disease: results from SOLUTION-1, a prospective IG-IBD study. <i>Journal of Crohns and Colitis</i> , <b>2014</b> , 8, 1642-52	1.5	17
57	Effectiveness and safety of Ustekinumab for the treatment of Crohn's disease in real-life experiences: a meta-analysis of observational studies. <i>Expert Opinion on Biological Therapy</i> , <b>2020</b> , 20, 193-203	5.4	16
56	Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience. <i>Scandinavian Journal of Gastroenterology</i> , <b>2017</b> , 52, 981-987	2.4	15

55	Inflammatory Bowel Disease Onset During Secukinumab Treatment: Real Concern or Just an Expression of Dysregulated Immune Response?. <i>Clinical Drug Investigation</i> , <b>2019</b> , 39, 799-803	3.2	15
54	Ustekinumab in the management of Crohn's disease: Expert opinion. <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 653-660	3.3	14
53	Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). <i>Drugs and Aging</i> , <b>2020</b> , 37, 383-392	4.7	12
52	Is Epstein-Barr virus infection associated with the pathogenesis of microscopic colitis?. <i>Journal of Clinical Virology</i> , <b>2017</b> , 97, 1-3	14.5	11
51	A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis. <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 1292-1298	3.3	11
50	Multidisciplinary management of patients with coexisting inflammatory bowel disease and spondyloarthritis: A Delphi consensus among Italian experts. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 1298-1305	3.3	10
49	Adalimumab in steroid-dependent Crohn's disease patients: prognostic factors for clinical benefit. <i>Inflammatory Bowel Diseases</i> , <b>2012</b> , 18, 826-31	4.5	10
48	Factors Affecting Clinical and Endoscopic Outcomes of Placebo Arm in Trials of Biologics and Small Molecule Drugs in Ulcerative Colitis: A Meta-Analysis. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, 987-997	4.5	10
47	Toxic megacolon and human Cytomegalovirus in a series of severe ulcerative colitis patients. <i>Journal of Clinical Virology</i> , <b>2015</b> , 66, 103-6	14.5	9
46	The Addition of an Immunosuppressant After Loss of Response to Anti-TNF Monotherapy in Inflammatory Bowel Disease: A 2-Year Study. <i>Inflammatory Bowel Diseases</i> , <b>2018</b> , 24, 394-401	4.5	9
45	Management of patients with complex perianal fistulas in Crohn's disease: Optimal patient flow in the Italian clinical reality. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 506-515	3.3	9
44	COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinants in a National Survey of the Italian IBD Patients Association. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> ,	4.5	9
43	Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 510-515	3.3	9
42	Risk factors and timing for colectomy in chronically active refractory ulcerative colitis: A systematic review. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 613-620	3.3	8
41	Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study. <i>United European Gastroenterology Journal</i> , <b>2020</b> , 8, 1045-1055	5.3	8
40	Letter: SPOSIB SB2-a Sicilian prospective observational study of IBD patients treated with infliximab biosimilar SB2. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 234-236	6.1	8
39	Physicians' Knowledge and Application of Immunization Strategies in Patients with Inflammatory Bowel Disease: A Survey of the Italian Group for the Study of Inflammatory Bowel Disease. <i>Digestion</i> , <b>2020</b> , 101, 433-440	3.6	8
38	Are we choosing wisely for inflammatory bowel disease care? The IG-IBD choosing wisely campaign. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 44-50	3.3	7

37	Selective Use of Combination Therapy in Patients With Infliximab-resistant Inflammatory Bowel Disease: Data From a Tertiary Referral Center. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 914	6.9	7
36	The Selective Use of Combination Therapy in Patients with Inflammatory Bowel Disease Resistant to Anti-TNF: to Whom, How and How Long?. <i>Journal of Crohns and Colitis</i> , <b>2016</b> , 10, 1451	1.5	7
35	Translation and initial validation of the Medication Adherence Report Scale (MARS) in Italian patients with Crohn's Disease. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 640-647	3.3	7
34	A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2021</b> , 36, 105-111	4	7
33	Ustekinumab in Crohn's disease: Real-world outcomes from the Sicilian network for inflammatory bowel diseases. <i>JGH Open</i> , <b>2021</b> , 5, 364-370	1.8	7
32	The biologics of ulcerative colitis. <i>Expert Opinion on Biological Therapy</i> , <b>2017</b> , 17, 175-184	5.4	6
31	Lupus-like reactions in patients with inflammatory bowel disease treated with anti-TNFs are insidious adverse events: data from a large single-center cohort. <i>Scandinavian Journal of Gastroenterology</i> , <b>2019</b> , 54, 1102-1106	2.4	6
30	Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease. <i>Advances in Therapy</i> , <b>2018</b> , 35, 545-562	4.1	6
29	Frequency of thiopurine methyltransferase mutation in patients of Mediterranean area with inflammatory bowel disease and autoimmune disorders. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 1506-1509 <sup>3.3</sup>	3.3	6
28	Risk of Pneumonia Caused by <i>Pneumocystis jiroveci</i> in Inflammatory Bowel Disease: The Role of Concomitant Pulmonary Comorbidities. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 571-572	6.9	6
27	Could Patients With Inflammatory Bowel Disease Treated With Immunomodulators or Biologics Be at Lower Risk for Severe Forms of COVID-19?. <i>Gastroenterology</i> , <b>2021</b> , 160, 1877-1878	13.3	6
26	A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 1461-1466	3.3	5
25	The METEOR Trial: The Burial of Methotrexate in Ulcerative Colitis?. <i>Gastroenterology</i> , <b>2016</b> , 151, 211-2	13.3	5
24	Biosimilars: The viewpoint of Italian patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 1304-1309	3.3	5
23	Unmet needs of Italian physicians managing patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 212-217	3.3	5
22	Effectiveness and safety of biologics in pediatric inflammatory bowel disease: Real-life data from the Sicilian Network. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2020</b> , 44, 223-229	2.4	5
21	Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus. <i>Gastroenterology Research and Practice</i> , <b>2019</b> , 2019, 3108025	2	4
20	Prevalence and incidence of inflammatory bowel disease in two Italian islands, Sicily and Sardinia: A report based on health information systems. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 1270-1274	3.3	4

19	Six year adalimumab efficacy in steroid-dependent Crohn's disease patients: A prospective single-center real life study. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 1314-1317	3.3	4
18	Increased risk of pneumonia among patients with inflammatory bowel disease: a comparison between patients treated with biologic therapies and with conventional drugs. <i>Journal of Crohn's and Colitis</i> , <b>2013</b> , 7, e405-6	1.5	4
17	Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF-inhibitors and conventional immunosuppressants. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 157-162	3.3	3
16	Suboptimal performance of APRI and FIB-4 in ruling out significant fibrosis and confirming cirrhosis in HIV/HCV co-infected and HCV mono-infected patients. <i>Infection</i> , <b>2019</b> , 47, 409-415	5.8	3
15	Head-to-head comparison of biological drugs for inflammatory bowel disease: from randomized controlled trials to real-world experience. <i>Therapeutic Advances in Gastroenterology</i> , <b>2021</b> , 14, 17562848211010668	4.7	3
14	Endoscopic rescue treatment in a pregnant ulcerative colitis patient with a severe colonic stricture: a conservative approach to bring the pregnancy to term. <i>Gastrointestinal Endoscopy</i> , <b>2017</b> , 86, 1183-1185	5.2	2
13	Barriers to anti-TNFalpha prescription among Italian physicians managing inflammatory bowel disease. <i>GastroHep</i> , <b>2019</b> , 1, 93-99	1	2
12	How clinicians and pathologists interact concerning inflammatory bowel disease in Italy: An IG-IBD survey. <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 734-736	3.3	2
11	Ozanimod for Ulcerative Colitis.. <i>New England Journal of Medicine</i> , <b>2022</b> , 386, 194	59.2	2
10	Anti-TNF combination therapy in inflammatory bowel disease: de novo or selective?. <i>Minerva Gastroenterologica E Dietologica</i> , <b>2019</b> , 65, 291-297	1.6	2
9	Effectiveness of Ustekinumab on Crohn's Disease Associated Spondyloarthritis: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). <i>Expert Opinion on Biological Therapy</i> , <b>2020</b> , 20, 1381-1384	5.4	2
8	Ustekinumab for treating ulcerative colitis: an expert opinion. <i>Expert Opinion on Biological Therapy</i> , <b>2020</b> , 20, 1321-1329	5.4	2
7	A Systematic Review on Infliximab Biosimilar SB2: From Pre-Clinical Data to Real-World Evidence. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> ,	5.4	2
6	Letter: psoriasiform eruption during vedolizumab therapy. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 342-343	6.1	1
5	SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2021</b> , 36, 3041-3049	4	1
4	Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19.. <i>Inflammatory Bowel Diseases</i> , <b>2022</b> ,	4.5	1
3	Letter: propensity score-handle with care. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 53, 360-361	6.1	1
2	Herpes Zoster Eruption During Vedolizumab Therapy: A Simple Coincidence or More?. <i>Inflammatory Bowel Diseases</i> , <b>2020</b> , 26, e51-e52	4.5	0

- 1 The VERSIFY Trial: What About Ultrasound Assessment?. *Gastroenterology*, **2020**, 158, 1176-1177 133